Literature DB >> 21099169

Loss of clusterin limits atherosclerosis in apolipoprotein E-deficient mice via reduced expression of Egr-1 and TNF-α.

Narisato Hamada1, Masaaki Miyata, Hideyuki Eto, Yoshiyuki Ikeda, Takahiro Shirasawa, Yuichi Akasaki, Takahiro Miyauchi, Yuko Furusho, Aya Nagaki, Bruce Jefferson Aronow, Chuwa Tei.   

Abstract

AIM: Whether clusterin/apolipoprotein J is antiatherogenic or proatherogenic is controversial. We reported that clusterin was markedly induced in media and neointima after vascular injury and that reduced clusterin expression reduced the proliferation of vascular smooth muscle cells (VSMCs), which induced G1 arrest via p53 and p21. The purpose of this study was to investigate the physiological function of clusterin in atherosclerosis using double-knockout mice (D-KO) of apolipoprotein E-deficient mice (apoE-KO) and clusterin-deficient mice (CLU-KO). METHODS AND
RESULTS: Atherosclerotic lesions in the aortic root were quantitated at 20 weeks of age. Atherosclerotic lesions of D-KO were significantly smaller than those of apoE-KO (D-KO: 0.176±0.078 mm(2) vs. apoE-KO: 0.365±0.164 mm(2), p< 0.001). To identify underlying atherosclerotic mechanisms that were blocked by loss of clusterin, we performed immunohistochemical analysis of Egr-1. Egr-1 immunoreactivity in the nuclei of VSMCs in atherosclerotic lesions of apoE-KO was upregulated, whereas it was not in D-KO lesions. Western blotting demonstrated that the expression levels of Egr-1 and TNF-α in the D-KO were significantly lower than those in the apoE-KO. When VSMCs and macrophages were obtained from D-KO and apoE-KO, Western blotting showed that the expression levels of Egr-1 and TNF-α in VSMCs and macrophages of D-KO were significantly lower than those of apoE-KO.
CONCLUSION: Loss of clusterin strongly suppressed apoE-KO-induced atherosclerotic lesions at a step prior to the expression of Egr-1 and TNF-α, suggesting that clusterin is a candidate for an antiatherogenic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099169     DOI: 10.5551/jat.5819

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  12 in total

Review 1.  The role of complement activation in atherogenesis: the first 40 years.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 2.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

3.  Atherogenic ω-6 Lipids Modulate PPAR- EGR-1 Crosstalk in Vascular Cells.

Authors:  Jia Fei; Carla Cook; Miriah Gillespie; Bangning Yu; Khyra Fullen; Nalini Santanam
Journal:  PPAR Res       Date:  2011-10-26       Impact factor: 4.964

4.  Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathway.

Authors:  Hans Prochnow; Rene Gollan; Philipp Rohne; Matthias Hassemer; Claudia Koch-Brandt; Markus Baiersdörfer
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

5.  Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I.

Authors:  Omar Khalid; Moin U Vera; Philip L Gordts; N Matthew Ellinwood; Philip H Schwartz; Patricia I Dickson; Jeffrey D Esko; Raymond Y Wang
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

6.  Brain clusterin protein isoforms and mitochondrial localization.

Authors:  Sarah K Herring; Hee-Jung Moon; Punam Rawal; Anindit Chhibber; Liqin Zhao
Journal:  Elife       Date:  2019-11-18       Impact factor: 8.140

7.  Integrative bioinformatics analysis of genomic and proteomic approaches to understand the transcriptional regulatory program in coronary artery disease pathways.

Authors:  Rajani Kanth Vangala; Vandana Ravindran; Madan Ghatge; Jayashree Shanker; Prathima Arvind; Hima Bindu; Meghala Shekar; Veena S Rao
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

8.  Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects.

Authors:  Graziella E Ronsein; Tomas Vaisar; W Sean Davidson; Karin E Bornfeldt; Jeffrey L Probstfield; Kevin D O'Brien; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-06-17       Impact factor: 10.514

Review 9.  Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature.

Authors:  Richard Lathe; Alexandra Sapronova; Yuri Kotelevtsev
Journal:  BMC Geriatr       Date:  2014-03-21       Impact factor: 3.921

Review 10.  Apolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease?

Authors:  Ning Yang; Qin Qin
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.